搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human placental protein 13,PP13 ELISA Kit

Human placental protein 13,PP13 ELISA Kit

  • 中文名稱：
    人胎盤蛋白13(PP13)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-E12733h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3800/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人胎盤蛋白13(PP13)酶聯(lián)免疫試劑盒（CSB-E12733h）為競(jìng)爭(zhēng)法ELISA試劑盒，定量檢測(cè)血清、尿液、組織勻漿樣本中的LGALS13含量。試劑盒檢測(cè)范圍為3.9 pg/mL-1000 pg/mL，適用于科研領(lǐng)域中對(duì)妊娠相關(guān)疾病的機(jī)制研究、生物標(biāo)志物篩選及病理模型評(píng)估?？蔀樘ケP功能研究、母胎界面分子調(diào)控探索提供高靈敏度的定量分析工具。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見(jiàn)產(chǎn)品說(shuō)明書(shū)。
  • 別名：
    GAL 13 ELISA Kit; Gal-13 ELISA Kit; GAL13 ELISA Kit; Galactoside binding soluble lectin 13 ELISA Kit; Galactoside-binding soluble lectin 13 ELISA Kit; Galectin-13 ELISA Kit; Galectin13 ELISA Kit; Lectin galactoside binding soluble 13 ELISA Kit; LGALS 13 ELISA Kit; LGALS13 ELISA Kit; PLAC 8 ELISA Kit; PLAC8 ELISA Kit; Placental protein 13 ELISA Kit; Placental tissue protein 13 ELISA Kit; PP13 ELISA Kit; PP13_HUMAN ELISA Kit
  • 縮寫(xiě)：
    LGALS13
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, urine, tissue homogenates
  • 檢測(cè)范圍：
    3.9 pg/mL-1000 pg/mL
  • 靈敏度：
    3.9 pg/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Cell Biology
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Competitive
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Binds beta-galactoside and lactose. Strong inducer of T-cell apoptosis. Has hemagglutinating activity towards chicken erythrocytes.
  • 基因功能參考文獻(xiàn)：
    1. Galectin-13 does not bind beta-galactosides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138. PMID: 29343868
    2. First-trimester PP-13 levels are significantly correlated with BMI and smoking. These correlations appear independent of uterine and umbilical artery resistance. In low risk patients, PP-13 levels fail to predict the risk for pre-eclampsia or small for gestational age (SGA) neonates. PMID: 26910737
    3. Gal-3 was significantly downregulated only in the extravillous trophoblast of intrauterine growth restriction ( IUGR) placentas. In contrast, expressions of gal-2 and gal-13 were downregulated in both villous and extravillous trophoblast cells of IUGR placentas. PMID: 27070577
    4. Placental protein 13 was localized to syncytiotrophoblasts in the chorionic villi and to occasional multinucleated luminal trophoblasts within converted decidual spiral arterioles in preeclampsia patients. PMID: 21989657
    5. study provides a basis for replenishing patients at risk for preeclampsia by the full length but not the truncated PP13 PMID: 25079598
    6. inadequate sensitivity as first trimester serum marker for pre-eclampsia PMID: 24786703
    7. As gal-13 with its anti-inflammatory functions plays a role in maternal immune system, a lack of gal-13 may contribute to an imbalance in inflammation processes in the placenta during pregnancy and therefore influences development of gestational diabetes. PMID: 25499680
    8. Evaluation of placental protein 13 (PP13) and risk factors as markers for predicting preeclampsia. PMID: 24607918
    9. Among singletons with severe preeclampsia, levels were significantly reduced, however, among twins, only a non-significant tendency for a reduction was recorded. PMID: 23729534
    10. Data in rats suggest that human LGALS13 plays role in maintaining uteroplacental blood flow and plays possible role in facilitating proper adaptation of maternal vasculature to pregnancy. PMID: 23406577
    11. The maternal serum level of placental protein 13 is significantly lower in Egyptian patients with pre-eclampsia compared to controls. PMID: 22460234
    12. secretion of PAPP-A, ADAM12 and PP13 is closely related to the size of the placenta in the beginning of pregnancy. After 8 weeks of pregnancy, which is the time for luteoplacental shift, the correlation disappears. PMID: 22015022
    13. PP13 is released from the syncytiotrophoblast in preterm preeclampsia and HELLP, mimicked in BeWo cells by ischemic stress, suggesting PP13 is a placental alarmin. PMID: 21596368
    14. ABO blood group can alter PP13-bioavailability in blood PMID: 21799738
    15. PP13 was best in predicting early onset pre-eclampsia with a sensitivity of 79% at a 20% false positive rate. PMID: 21652068
    16. PP13 mRNA is lower in the third trimester at the time of disease while protein level accumulates and become higher creating an unparallel change in the level of the mRNA and the corresponding protein. PMID: 21257080
    17. PP13 levels were decreased in women with preeclampsia. PMID: 21257081
    18. PP13 is a suitable stable molecule and can be treated under routine laboratory and transport temperatures. PMID: 20509161
    19. gene polymorphism is associated with an increased risk of preterm labour PMID: 19818512
    20. multiples of the gestation-specific normal median significantly lower in trisomy 18 and 13 pregnancies PMID: 19844942
    21. level in preeclampsia was significantly lower than that in controls PMID: 19813218
    22. PP13 is implicated in the pathogenesis of impaired placentation and subsequent development of early-preeclampsia but measurement of this placental product is unlikely to be useful in screening for the disease at 11-13 weeks. PMID: 19777530
    23. The primary structure of the newly sequence analysed placental tissue protein 13 (PP13) was highly homologous to several members of the beta-galactoside-binding S-type lectin (galectin) family PMID: 11742106
    24. PP13/galectin-13 may have special haemostatic and immunobiological functions at the lining of the common feto-maternal blood-spaces or developmental role in the placenta. PMID: 15009185
    25. screening of maternal PP13 levels in the first trimester is a promising diagnostic tool for the prediction of preeclampsia with high sensitivity and specificity. PMID: 17618748
    26. Decreased levels of PP13 (placental protein 13) were not significantly correlated with the studied adverse pregnancy outcomes of intrauterine growth restriction, preterm delivery, low birth weight, and intrauterine fetal demise. PMID: 18186153
    27. Maternal serum PP13 concentration in the first trimester was significantly lower in patients who developed preterm and early-onset preeclampsia than in those with normal pregnancies. PMID: 18539259
    28. parallel to its decreased placental expression, an augmented membrane shedding of PP13 contributes to the increased third trimester maternal serum PP13 concentrations in women with preterm pre-eclampsia and HELLP syndrome. PMID: 18791734
    29. findings indicate that an alteration in the placental protein 13 (PP13) messenger RNA expression in the trophoblasts may be associated with the pathogenesis of preeclampsia PMID: 19087972

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cytoplasm. Nucleus matrix.
  • 組織特異性：
    Detected in adult and fetal spleen, fetal kidney, adult urinary bladder and placenta. Placental expression originates predominantly from the syncytiotrophoblast.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 15449

    OMIM: 608717

    KEGG: hsa:29124

    STRING: 9606.ENSP00000221797

    UniGene: Hs.23671